Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin’s disease developing resistance to pembrolizumab

Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin’s disease and significantly improved the proportion of patients with long-term disease control. However, there is no standardized therapeutic opti...

Descripció completa

Dades bibliogràfiques

Autors principals:	K. Reuthner, P. Aubele, K. Menhart, P. Rath, D. C. Harrer, W. Herr, J. Hahn, M. Vogelhuber, D. Heudobler, F. Lueke, A. Reichle, M. Grube
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-02-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	Hodgkin`s disease relapse pembrolizumab resistance MEPED remission
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1334233/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!